US 12,281,172 B2
Cross-species-specific PSMAxCD3 bispecific single chain antibody
Peter Kufer, Moosburg an der Isar (DE); Tobias Raum, Eurasburg (DE); Roman Kischel, Munich (DE); Ralf Lutterbüse, Neuried (DE); Patrick Hoffmann, Bad Heilbrunn (DE); Doris Rau, Munich (DE); Susanne Mangold, Cham (CH); Matthias Klinger, Gilching (DE); Evelyne Schaller, Munich (DE); Susanne Hausmann, Sauerlach (DE); Petra Fluhr, Dachau (DE); and Carola Steiger, Augsburg (DE)
Assigned to AMGEN RESEARCH (MUNICH) GMBH, Munich (DE)
Filed by AMGEN RESEARCH (MUNICH) GMBH, Munich (DE)
Filed on Apr. 2, 2021, as Appl. No. 17/221,627.
Application 17/221,627 is a continuation of application No. 16/020,558, filed on Jun. 27, 2018, abandoned.
Application 16/020,558 is a continuation of application No. 13/122,245, abandoned, previously published as PCT/EP2009/062793, filed on Oct. 1, 2009.
Claims priority of provisional application 61/101,857, filed on Oct. 1, 2008.
Prior Publication US 2023/0037742 A1, Feb. 9, 2023
Int. Cl. A61K 39/00 (2006.01); C07K 16/30 (2006.01)
CPC C07K 16/3069 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01)] 18 Claims
 
1. A bispecific single chain antibody molecule comprising a first binding domain that specifically binds to human CD3 epsilon (CD3ε) chain and a second binding domain that specifically binds to human prostate-specific membrane antigen (PSMA), wherein the first binding domain comprises a light chain variable (VL CD3ε) region comprising complementarity determining regions CDR-L1, CDR-L2, and CDR-L3 and a heavy chain variable (VH CD3ε) region comprising complementarity determining regions CDR-H1, CDR-H2, and CDR-H3, and wherein CDR-L1 has the sequence of SEQ ID NO: 171, CDR-L2 has the sequence of SEQ ID NO: 172, CDR-L3 has the sequence of SEQ ID NO: 173, CDR-H1 has the sequence of SEQ ID NO: 174, CDR-H2 has the sequence of SEQ ID NO: 175, and CDR-H3 has the sequence of SEQ ID NO: 176.